GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 341.9% in November

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,330,000 shares, an increase of 341.9% from the October 31st total of 301,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the short-interest ratio is currently 0.7 days.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX traded up $0.01 during trading on Thursday, hitting $2.71. 444,054 shares of the company traded hands, compared to its average volume of 2,469,405. The business’s fifty day moving average is $2.34 and its 200 day moving average is $2.68. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the prior year, the company posted ($4.80) EPS. Equities research analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GOVX. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a report on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. Noble Financial increased their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. Finally, D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Tuesday, November 19th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and an average target price of $14.20.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.